קו-דיובאן 16012.5 מג טבליות מצופות Israel - Hebräisch - Ministry of Health

קו-דיובאן 16012.5 מג טבליות מצופות

novartis israel ltd - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 160 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

קו-דיובאן 16025 מג טבליות מצופות Israel - Hebräisch - Ministry of Health

קו-דיובאן 16025 מג טבליות מצופות

novartis israel ltd - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 160 mg; hydrochlorothiazide 25 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

אמוקסי קאר פורטה 250 תרחיף Israel - Hebräisch - Ministry of Health

אמוקסי קאר פורטה 250 תרחיף

vitamed pharmaceutical industries ltd - amoxicillin as trihydrate - אבקה להכנת תרחיף - amoxicillin as trihydrate 250 mg / 5 ml - amoxicillin

פרימולוט-נור Israel - Hebräisch - Ministry of Health

פרימולוט-נור

bayer israel ltd - norethisterone acetate - טבליה - norethisterone acetate 5 mg - norethisterone - norethisterone - oral progestron for: dysfunctional bleeding, primary and secondary amenorrhea, premenstrual syndrome, timing of mensturation and endometriosis.

פולבסטרנט סנדוז Israel - Hebräisch - Ministry of Health

פולבסטרנט סנדוז

novartis israel ltd - fulvestrant - תמיסה להזרקה - fulvestrant 50 mg/ml - fulvestrant

בינוקריט 1000 יחבל 0.5 מל Israel - Hebräisch - Ministry of Health

בינוקריט 1000 יחבל 0.5 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

בינוקריט 2000 יחבל 1 מל Israel - Hebräisch - Ministry of Health

בינוקריט 2000 יחבל 1 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 2000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

בינוקריט 30000 יחבל 0.75 מל Israel - Hebräisch - Ministry of Health

בינוקריט 30000 יחבל 0.75 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 30000 iu / 0.75 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

בינוקריט 4000 יחבל  0.4 מל Israel - Hebräisch - Ministry of Health

בינוקריט 4000 יחבל 0.4 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 4000 iu / 0.4 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

בינוקריט 5000 יחבל 0.5 מל Israel - Hebräisch - Ministry of Health

בינוקריט 5000 יחבל 0.5 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 5000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob